Abstract
Cardiac hypertrophy, interstitial fibrosis, and cardiac dysfunction ultimately lead to cardiac failure. Cardiac failure is one of the major causes of heart disease and death in our society. The molecular causes of heart diseases, like many other diseases, remain largely unknown. Recently, large-scale proteomics studies have been undertaken to better understand the underlying mechanisms of molecular causes of heart disease. Many protein alterations have already been identified in the human diseased myocardium. Further experiments on these proteins are ongoing to know their suitability for drug targets, therapeutic proteins, or disease biomarkers. This review deals with a proteomics perspective on human heart failure, and is divided into two parts. The first part provides a glimpse on proteomics technologies used for identification and quantification of proteins related to heart disease. The second part is the main focus of this review and deals with evolving biomarkers and clinical diagnostics, potential future drugs, clinical approaches in managing heart failure, and clinical shortcomings, which are discussed to some detail from the viewpoint of a medical doctor and proteomics scientists.
Keywords: Cardiac proteomics, human disease, two-dimensional gel electrophoresis, mass spectrometry, biomarkers, review
Current Proteomics
Title: Human Heart Failure: A Proteomics Perspective
Volume: 4 Issue: 3
Author(s): Arvind Goel, Randeep Rakwal and Ganesh Kumar Agrawal
Affiliation:
Keywords: Cardiac proteomics, human disease, two-dimensional gel electrophoresis, mass spectrometry, biomarkers, review
Abstract: Cardiac hypertrophy, interstitial fibrosis, and cardiac dysfunction ultimately lead to cardiac failure. Cardiac failure is one of the major causes of heart disease and death in our society. The molecular causes of heart diseases, like many other diseases, remain largely unknown. Recently, large-scale proteomics studies have been undertaken to better understand the underlying mechanisms of molecular causes of heart disease. Many protein alterations have already been identified in the human diseased myocardium. Further experiments on these proteins are ongoing to know their suitability for drug targets, therapeutic proteins, or disease biomarkers. This review deals with a proteomics perspective on human heart failure, and is divided into two parts. The first part provides a glimpse on proteomics technologies used for identification and quantification of proteins related to heart disease. The second part is the main focus of this review and deals with evolving biomarkers and clinical diagnostics, potential future drugs, clinical approaches in managing heart failure, and clinical shortcomings, which are discussed to some detail from the viewpoint of a medical doctor and proteomics scientists.
Export Options
About this article
Cite this article as:
Goel Arvind, Rakwal Randeep and Agrawal Kumar Ganesh, Human Heart Failure: A Proteomics Perspective, Current Proteomics 2007; 4 (3) . https://dx.doi.org/10.2174/157016407783221303
DOI https://dx.doi.org/10.2174/157016407783221303 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions
Current Pharmaceutical Design A Cell Culture Model for the Assessment of the Chemopreventive Potential of Dietary Compounds.
Current Nutrition & Food Science Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Vascular Pleiosynergy - Does It Really Work?
Current Vascular Pharmacology Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Different Patterns of Statin Use in Patients with Acute Myocardial Infarction
Current Vascular Pharmacology Metabolomics
Current Drug Metabolism Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design The Causal Relationship Between Passive Smoking and Inflammation on the Development of Cardiovascular Disease: A Review of the Evidence
Inflammation & Allergy - Drug Targets (Discontinued) Recent Development and Future Prospects of Plant-Based Vaccines
Current Drug Metabolism Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes
Inflammation & Allergy - Drug Targets (Discontinued) Inflammatory Responses to Respiratory Syncytial Virus (RSV) Infection and the Development of Immunomodulatory Pharmacotherapeutics
Current Medicinal Chemistry Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology